Trials / Completed
CompletedNCT02963506
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | |
| DRUG | Bimekizumab | Bimekizumab in different dosages. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-10-01
- Completion
- 2018-08-01
- First posted
- 2016-11-15
- Last updated
- 2023-06-06
- Results posted
- 2020-11-16
Locations
74 sites across 10 countries: United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT02963506. Inclusion in this directory is not an endorsement.